Trial reportDiabetes, obesity & metabolism2019
Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
Trial report in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Improvement in mood symptoms after post-bariatric surgery among people with obesity: A systematic review and meta-analysis.Diabetes/metabolism research and reviews · 2021Pooled it
- Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis.European journal of clinical pharmacology · 2021Pooled it
- Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.Metabolism: clinical and experimental · 2022Trial
- Branched-Chain Amino Acids in relation to food preferences and insulin resistance in obese subjects consuming walnuts: A cross-over, randomized, double-blind, placebo-controlled inpatient physiology study.Clinical nutrition (Edinburgh, Scotland) · 2021Trial
- Understanding Impact of Anti-Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Review
- New Insight into Selective Serotonin Receptor Agonists in the Central Nervous System, Studied with WAY163909 in Obese and Diabetic Wistar Rats.Brain sciences · 2023Article
- 5-HTNutrients · 2023Review
- Management of metabolic-associated fatty liver disease: The diabetology perspective.World journal of gastroenterology · 2023Review
- Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.Current obesity reports · 2022Review
- Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?Frontiers in endocrinology · 2022Review
- Serotonergic Regulation of Hepatic Energy Metabolism.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- The gastro-jejunal anastomosis site influences dumping syndrome and weight regain in patients with obesity undergoing Laparoscopic Roux-en-Y Gastric Bypass.Eating and weight disorders : EWD · 2021Article
- The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study.Acta diabetologica · 2021Article
- Role of serotonin in body weight, insulin secretion and glycaemic control.Journal of neuroendocrinology · 2021Review
- Central 5-HTR2C in the Control of Metabolic Homeostasis.Frontiers in endocrinology · 2021Review
- Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease.Frontiers in endocrinology · 2021Article
- Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function.International journal of molecular sciences · 2020Review
- Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review.Nutrients · 2020Review
- A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin-induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite-regulating hormones and mRNA expression of the 5-hydroxytryptamine 2c receptor (5-HT2c receptor). A total of 48 obese participants were enrolled in this six-month, randomized (1:1), placebo-controlled, double-blinded clinical trial. Lorcaserin treatment reduced fat mass (P < 0.001), the fatty liver index (P < 0.0001) and energy intake (P < 0.03) without affecting energy expenditure or lean mass. Total low-density lipoprotein (LDL) (P < 0.04) and small LDL particles (P < 0.03) decreased, while total high-density lipoprotein (HDL) P < 0.02) increased and heart rate significantly decreased with lorcaserin treatment. No mRNA expression of the 5-HT2c receptor was observed in peripheral organs. These data suggest that lorcaserin treatment for six months improves cardiometabolic health in obese individuals, acting mainly through the brain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.